The genetic constructs switch on only in cancer cells and force them to become  “factories”  that produce any signal protein of choice, encoded in the genetic sequence. The proteins are used for activating the immune system against the cancer to kill it.
For that, activating exclusively in cancer cells is critical – yet determining the difference between cancer cells and healthy cells is not a, but arguably the most important question in cancer.  Earli has demonstrated an exceptionally high specificity and sensitivity level of its genetic constructs across human cancer samples, followed by strong efficacy against tumors in multiple pre-clinical models.

Existing immune oncology drugs are powerful weapons in the fight against cancer.  When they work, they can sometimes cure even late stage cancer patients. Yet unfortunately, only 30-40% of patients respond at all to them. They all rely on natural biomarkers to recognize the tumor, but they are often not targetable with drugs, or not existent at all.  Earli is designed to activate the patients’ immune system   from within the cancer , and teach the immune system to attack it, essentially turning cancer against itself.

Finally, we are taking control of the cancer and "tell it” to make any synthetic therapeutic agent of choice.  That can save hundreds of thousands of lives per year.